Citicoline has one of the larger human clinical trial bases of any nootropic-adjacent supplement, spanning more than three decades of research across stroke recovery, cognitive impairment, mood disorders, and healthy-adult performance. The size of that evidence base is unusual for an over-the-counter compound—most of it originates from citicoline’s decades-long use as a prescription drug in Europe and Japan before it reached the U.S. supplement market.
This article summarizes what the published human trials actually found, organized by the population studied, rather than by marketing claim. It is informational only and does not constitute medical advice; citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent any disease.
Key Takeaways
- Citicoline’s largest clinical trial base is in acute ischemic stroke, including multiple randomized, placebo-controlled Phase III trials and Cochrane-level systematic reviews.
- A 2021 randomized, double-blind, placebo-controlled trial in healthy older adults found citicoline supported specific memory measures at standard doses [1].
- Meta-analyses in dementia and mild cognitive impairment report modest but consistent cognitive benefits, though trial quality varies [2].
- Smaller randomized trials have tested citicoline as an add-on therapy in bipolar disorder with comorbid substance use, with mixed results [3].
- Most positive trials enrolled older adults or people with existing cognitive or cerebrovascular conditions; evidence in healthy young adults is comparatively thin.
Stroke and Cerebrovascular Trials
The largest and most rigorous citicoline trials were conducted in acute ischemic stroke. An early randomized efficacy trial established a dose-response signal at 500–2000 mg/day [4], followed by a Phase III trial testing a 2000 mg dose in a larger cohort [5]. A pooled analysis of individual patient data across several trials found a modest but statistically detectable improvement in the odds of complete recovery at three months [6].
More recent evidence has been less favorable. A formal meta-analysis of randomized, double-blind, placebo-controlled trials found the pooled effect on functional outcome was not statistically significant when only the highest-quality trials were included [7], and a 2020 Cochrane systematic review concluded that citicoline probably has little or no effect on death or dependence after stroke, while noting the evidence certainty was low to moderate [8]. A subsequent 2022 randomized controlled trial found improvements in some neurological outcome measures but not others [9]. Taken together, the stroke literature illustrates a common pattern: early, smaller positive trials followed by larger or more rigorously pooled analyses that temper the initial effect size.
Cognitive Impairment and Dementia Trials
A randomized, double-blind, placebo-controlled trial in healthy older adults (mean age in the 50s–60s) found that 12 weeks of citicoline supplementation improved specific measures of episodic memory relative to placebo, with a larger effect in participants who had lower baseline memory scores [1]. This is one of the more methodologically rigorous trials conducted in a non-clinical population rather than diagnosed dementia patients.
In diagnosed populations, a systematic review and meta-analysis assessing citicoline’s role in preventing or slowing dementia found a statistically significant, if modest, benefit on global cognitive scores across pooled studies [2]. A separate 2025 systematic review and meta-analysis comparing citicoline to a related compound, choline alphoscerate, in dementia patients found both produced measurable cognitive improvement, without establishing clear superiority of one over the other [10]. Earlier pilot work, including the CITIMEM study, explored citicoline as an adjunct to standard dementia pharmacotherapy with encouraging but preliminary results [11].
Mood, Substance Use, and Psychiatric Trials
Two related randomized, placebo-controlled trials tested citicoline as an add-on therapy in people with bipolar disorder and comorbid substance dependence. The first, in outpatients with bipolar disorder and cocaine dependence, found citicoline associated with reduced cocaine use over the trial period, though effects on mood symptoms were less clear [3]. A follow-up trial in bipolar and unipolar depression with comorbid methamphetamine dependence found similar patterns—some benefit on substance-use outcomes, more modest effects on depressive symptoms [12]. These trials are notable for testing citicoline outside the cognitive-decline context, but the sample sizes were small and the populations narrow, so the findings should not be generalized to citicoline’s effects on mood in the general population.
Healthy-Adult and Attention Trials
Trials in healthy, non-clinical populations are fewer and generally smaller in scale. A randomized trial in adolescent males found short-term citicoline supplementation associated with improved motor speed and attention task performance [13]. A pilot study using a citicoline-caffeine beverage reported improvements in concentration, working memory, and sustained attention in healthy adults [14], though the combined formulation makes it difficult to isolate citicoline’s independent contribution from caffeine’s well-established stimulant effects.
What This Body of Evidence Does and Doesn’t Support
Reading across the trial landscape, the most consistent signal is in older adults with age-related cognitive changes or existing cerebrovascular disease, where multiple independent trials and meta-analyses converge on a modest positive effect. The stroke-recovery evidence is more mixed than early trials suggested, with the most rigorous recent syntheses finding smaller or non-significant effects. Evidence in healthy young adults exists but is limited in both trial count and sample size, meaning claims about citicoline’s effects on peak cognitive performance in this population rest on thinner data than claims about age-related decline.
Neither this article nor any product mentioned is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare provider before starting any new supplement.
Frequently Asked Questions
How many human clinical trials exist for citicoline?
Dozens, spanning acute ischemic stroke, vascular and age-related cognitive decline, dementia, mild cognitive impairment, and smaller trials in mood and substance-use disorders. Stroke has the largest trial base, including multiple Phase III trials and Cochrane-level systematic reviews.
Does citicoline work for stroke recovery according to trials?
Early trials and pooled analyses reported modest benefit, but more recent, methodologically stricter syntheses, including a 2020 Cochrane review, found the effect on death or dependence after stroke was small or not statistically significant. The evidence has weakened, not strengthened, as trial quality has improved.
Is there clinical trial evidence for citicoline in healthy adults?
Some, but it is thinner than the evidence in older or clinical populations. A randomized trial in healthy older adults found memory benefits, and smaller trials in adolescents and healthy adults using combination formulations reported improvements in attention and working memory, though isolating citicoline’s independent effect in combination trials is difficult.
Does citicoline help with dementia in clinical trials?
Meta-analyses report a modest, statistically significant benefit on global cognitive scores in dementia populations, and a 2025 comparison trial found effects similar to choline alphoscerate. Effect sizes are generally small and trial quality across the pooled studies varies.
References
- Nakazaki E et al. The Journal of nutrition (2021). PMID 33978188
- Bonvicini M et al. Nutrients (2023). PMID 36678257
- Brown ES et al. Journal of clinical psychopharmacology (2007). PMID 17873684
- Clark WM et al. Stroke (1999). PMID 10582983
- Clark WM et al. Neurology (2001). PMID 11706098
- Dávalos A et al. Stroke (2002). PMID 12468781
- Secades JJ et al. Journal of stroke and cerebrovascular diseases (2016). PMID 27234918
- MartÃ-Carvajal AJ et al. The Cochrane database of systematic reviews (2020). PMID 32860632
- Agarwal A et al. PloS one (2022). PMID 35639720
- Sagaro GG et al. Frontiers in neurology (2025). PMID 41426989
- Gareri P et al. Archives of gerontology and geriatrics (2020). PMID 32447126
- Brown ES et al. Journal of affective disorders (2012). PMID 22974472
- McGlade E et al. Journal of attention disorders (2019). PMID 26179181
- Bruce SE et al. International journal of food sciences and nutrition (2014). PMID 25046515
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
